TFS
REGN icon

Thoroughbred Financial Services’s Regeneron Pharmaceuticals REGN Stock Holding History

Thoroughbred Financial Services’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-680
Closed -$431K – 676
2025
Q1 		$431K Buy
680
+88
+15% +$60.5K 0.03% 455
2024
Q4 		$421K Buy
592
+102
+21% +$85.6K 0.03% 451
2024
Q3 		$515K Hold
490
– – 0.03% 387
2024
Q2 		$515K Buy
+490
New +$475K 0.03% 379
2024
Q1 		– Sell
-498
Closed -$437K – 573
2023
Q4 		$437K Sell
498
-6
-1% -$4.94K 0.04% 390
2023
Q3 		$414K Buy
+504
New +$396K 0.04% 359

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Thoroughbred Financial Services's REGN Position: Q2 2025 in Review

Thoroughbred Financial Services sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 680 shares — an estimated $431K sold.

Thoroughbred Financial Services first reported a position in REGN in Q3 2023 and held it in 6 quarters. The position peaked at $515K in Q3 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • Thoroughbred Financial Services reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Thoroughbred Financial Services sold 680 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $431K.
  • Thoroughbred Financial Services first reported a position in Regeneron Pharmaceuticals in Q3 2023 and held it in 6 quarters.
  • Thoroughbred Financial Services's Regeneron Pharmaceuticals position peaked at $515K in Q3 2024.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Thoroughbred Financial Services's 13F filing for Q2 2025, filed 8 Aug 2025.